贝前列素联合匹伐他汀治疗慢性阻塞性肺疾病相关肺动脉高压的效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (556 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of Beraprost and Pitavastatin in the treatment of chronic obstructive pulmonary disease (COPD) -related pulmonary hypertension. Methods A total of 100 COPD-related pulmonary hypertension patients admitted to the First Hospital of Nanchang from December 2019 to December 2020 were selected as the research subjects. They were divided into an observation group and a control group according to the principle of random drawing, with 50 cases in each group. Patients in the observation group were treated with Beraprost combined with Pitavastatin, and patients in the control group were treated with Beraprost. The total effectiveness rate, lung function indexes, and inflammatory factors of the two groups of patients were compared. Results The total effectiveness rate of treatment in the observation group was higher than that in the control group, the difference was statistically significant(P＜0.05). The forced expiratory volume in the first second (FEV1), the forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) and percentage of predicted value of the FEV1 (FEV1%) of the observation group were higher than those of the control group, the differences were statistically significant (P＜0.05). The indexes of blood neutrophils,interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in patients with COPD-related pulmonary hypertension in the observation group were lower than those in the control group, the differences were statistically significant (P＜0.05).Conclusion Compared with Beraprost monotherapy, the combination of Beraprost and Pitavastatin has a better effect in the treatment of COPD-related pulmonary hypertension, which can improve the patients′ lung function indicators.

Key words： Beraprost Pitavastatin Pulmonary hypertension Treatment Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Lihua
	CHEN Yuanhui
	LI Ying

Cite this article:

LI Lihua,CHEN Yuanhui,LI Ying. Effect of Beraprost combined with Pitavastatin in the treatment of chronic obstructive pulmonary disease-related pulmonary hypertension[J]. 中国当代医药, 2022, 29(2): 45-47转51.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2022/V29/I2/45

[1]	王燕，黄旭晴，徐长青，等.辛伐他汀联合阿奇霉素治疗老年慢性阻塞性肺疾病合并肺动脉高压患者的临床研究[J].中国临床药理学杂志，2020，36（17）：2606-2609.
[2]	童楚恒，洪永设.信必可联合辛伐他汀治疗COPD 的效果及对患者肺功能的影响[J].中外医学研究，2020，18（9）：120-122.
[3]	陈洁，吴媖.阿奇霉素结合辛伐他汀在慢性阻塞性肺疾病合并肺动脉高压患者治疗中的应用[J].心理月刊，2020，15（4）：188.
[5]	何洁，严玲，杨屹云，等.阿托伐他汀对老年慢性阻塞性肺疾病继发肺动脉高压患者肺功能、血管内皮功能和炎症因子的影响[J].现代生物医学进展，2020，20（5）：980-983.
[6]	李婕，赵磊.前列地尔对慢性阻塞性肺疾病合并肺动脉高压患者呼气冷凝液中内皮素-1、白介素-6 的影响[J].安徽医科大学学报，2017，52（6）：892-896.
[7]	陈妤，梁世廉，黄献欢，等.COPD 合并肺动脉高压患者NLR、MSTN、TXB2、NT-proBNP 的变化及其意义[J].解放军预防医学杂志，2019，37（4）：55-56.
[8]	廖志平，李星洪，程娟敏，等.匹伐他汀联合阿司匹林治疗颈动脉粥样硬化的临床研究[J].吉林医学，2019，40（1）：81-83.
[4]	李文，周金阁，胡豆豆，等.阿托伐他汀联合补肺益肾方对慢性阻塞性肺疾病合并肺动脉高压患者血清炎症因子，血管内皮功能及右心室重塑的影响[J].现代中西医结合杂志，2020，29（18）：1977-1982.
[9]	祖玉刚，赵淑君，张芳，等.匹伐他汀联合乙酰半胱氨酸对PCI 患者对比剂肾功能损伤的干预作用[J].山东医药，2018，1107（33）：55-58.
[10]	周静.匹伐他汀联合依折麦布治疗老年冠心病合并糖尿病疗效和安全评价[J].名医，2019，70（3）：236，238.
[11]	张玉蓉，高荣敏，陈家艺，等.匹伐他汀联合血必净注射液对急性冠脉综合征病人行PCI 术后疗效观察[J].内蒙古医学院学报，2018，40（1）：50-54，61.
[12]	范学秀，祖玉刚.匹伐他汀联合乙酰半胱氨酸对经皮冠脉介入诊疗术患者对比剂肾病的治疗研究[J].中国循证心血管医学杂志，2019，11（11）：1345-1348.
[13]	赵露茜，朱国栋，李庆云，等.匹伐他汀联合缬沙坦治疗早期糖尿病肾病的临床研究[J].辽宁医学杂志，2018，32（4）：31-33.
[14]	韦涛.匹伐他汀钙联合谷维素对32 例高胆固醇血症患者血脂水平的影响[J].上海医药，2017，38（11）：20-22，47.
[15]	刘立新，田国祥，武云涛，等.匹伐他汀联合依折麦布或多廿烷醇治疗老年心血管疾病的效果对比[J].中国临床保健杂志，2021，24（3）：328-332.
[16]	章范满，池秀婷.匹伐他汀治疗血脂异常合并高血压患者的疗效及安全性评价[J].中国保健营养，2020，30（2）：283-284.
[17]	冯翔，姜睿，潘世伟，等.两种剂量匹伐他汀强化降脂对冠状动脉旁路移植术后早期代谢、安全性及预后影响的比较[J].心脏杂志，2020，32（2）：124-127.
[18]	张鲲.匹伐他汀片与阿托伐他汀片治疗高胆固醇血症的经济学分析[J].中国农村卫生，2020，12（4）：83.